Logo.png
GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions
October 05, 2023 08:45 ET | GRI Bio, Inc.
In several murine models of chronic inflammation and fibrosis, as well as in humans, it has been shown that iNKT cells are selectively activated in the disease setting Data supports GRI Bio’s...
Transparency Market Research
Autoimmune Disease Diagnostics Market Surges at 3.8% CAGR from 2019 to 2027 Fueled by Heightened Public Awareness: TMR Report
September 22, 2023 10:36 ET | Transparency Market Research
Wilmington, Delaware, United States, Sept. 22, 2023 (GLOBE NEWSWIRE) -- The autoimmune disease diagnostics market was estimated to have acquired US$ 14.4 billion in 2018.  It is anticipated to...
scinai logo whitespace border (002).jpg
Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
September 19, 2023 16:05 ET | Scinai Immunotherapeutics Ltd.
JERUSALEM, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing...
Scinai Yahoo@4x300x400
Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results
September 13, 2023 16:13 ET | Scinai Immunotherapeutics Ltd.
Scinai’s NanoAbs downregulated key molecular markers overexpressed in plaque psoriasis Stratum corneum regained normal appearance in laboratory 3D skin model Results from ex-vivo study...
Scinai Logo.jpg
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
September 06, 2023 06:00 ET | BiondVax Pharmaceuticals Ltd.
JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to...
Folia Health Announces Expansion of HD, MS, MG cohorts
Folia Health Reinforces Commitment to Autoimmune and Neurological Conditions: Announcing the Expansion of Multiple Sclerosis, Huntington's Disease, and Myasthenia Gravis User Cohorts
September 05, 2023 09:00 ET | Folia Health
BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Folia Health, a patient-focused health technology company, proudly announces a user cohort expansion of 3 conditions of great unmet need: Multiple...
AMR Logo.png
Patented Drugs Market to Reach $1,456.4 Billion, Globally, by 2032 at 6% CAGR: Allied Market Research
August 10, 2023 02:59 ET | Allied Market Research
Portland, OR, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Patented Drugs Market By Dosage Form (Solid Drug Product, Liquid Drug Product, and Others), By...
BiondVax LOGO.png
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
August 01, 2023 16:01 ET | BiondVax Pharmaceuticals Ltd.
JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative...
Logo.png
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
July 24, 2023 09:00 ET | GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio management team on Thursday, July 27th at 1:00 PM ET LA JOLLA, CA, July 24, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio”...
Research Nester Logo.jpg
Bispecific Antibody Market revenue to cross USD 1 Billion by 2035, says Research Nester
July 24, 2023 07:00 ET | Research Nester
New York, July 24, 2023 (GLOBE NEWSWIRE) -- The global bispecific antibody market size is slated to expand at ~7% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 1...